Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYSARI
2022-501315-13-00Phase 3Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of tretinoin in head and neck squamous cell carcinoma (HNSCC), oropharyngeal squamous cell carcinoma (OPSCC), laryngeal squamous cell carcinoma (LSCC) and 1 more (4 arms), sponsored by Centre Léon Bérard. Primary endpoint: Event-free survival. Planned start Mar 2025; status: authorised.
02
Drugs
tretinoin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)oropharyngeal squamous cell carcinoma (OPSCC)laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on 2022-501315-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501315-13-00.